Telesis Bio Inc.: debt financing — Telesis Bio amends debt agreements, raises interest margins; annual meeting elects directors

The Term Loan Second Amendment, among other changes, (i) amends certain funding conditions with respect to the remaining term loans available for borrowing under the Term Loan Agreement, (ii) increases the interest rate margin applicable to the term loans, (iii) increases the minimum interest rate and prepayment fees applicable to the term loans, and (iv) amends the minimum net revenue covenant under the Term Loan Agreement for certain reporting periods.

The Revolving Loan Second Amendment, among other changes, (i) increases the minimum interest rate, (ii) increases the early termination fee applicable to the revolving loan facility, and (iii) amends the minimum net revenue covenant under the Revolving Loan Agreement for certain reporting periods.

and (ii) Amendment No. 2 to Credit, Security and Guaranty Agreement (Revolving Loan) (the Revolving Loan Second Amendment, and together with the Term Loan Second Amendment, the Second Amendments), which amends that certain Credit, Security and Guaranty Agreement (Revolving Loan), dated as of August 9, 2022 (as amended, restated, supplement or otherwise modified from time to time, the Revolving Loan Agreement, and together with the Term Loan Agreement, the Loan Agreements) among the Company, EtonBio, certain subsidiaries of the Company that may become party thereto from time to time as borrowers or guarantors, the lenders party thereto from time to time (collectively, the Revolving Loan Lenders, and together with the Term Loan Lenders, the Lenders) and MidCap Funding IV Trust, as administrative agent (the Revolving Agent)

On June 30, 2023, Telesis Bio Inc. (the Company) entered into (i) Amendment No. 2 to Credit, Security and Guaranty Agreement (Term Loan) (the Term Loan Second Amendment), which amends that certain Credit, Security and Guaranty Agreement (Term Loan), dated as of August 9, 2022 (as amended, restated, supplemented or otherwise modified from time to time, the Term Loan Agreement), among the Company, EtonBio, Inc., a California corporation and the Company’s wholly-owned subsidiary (EtonBio and together with the Company, the Borrowers), certain subsidiaries of the Company that may become party thereto from time to time as borrowers or guarantors, the lenders party thereto from time to time (collectively, the Term Loan Lenders) and MidCap Financial Trust, as administrative agent (the Term Agent)

Proposal One – Election of Directors The table below presents the voting results of the election of the two Class II directors to the Company’s Board of Directors by the Company’s stockholders: Nominee Votes For Votes Withheld Percent of Voted Broker Non-Votes Andrea L. Jackson 18,602,921 506,147 76.64 % 5,162,928 Franklin R. Witney 18,558,271 550,797 76.45 % 5,162,928

Proposal Two – Ratification of Appointment of Independent Registered Public Accounting Firm The Company’s stockholders ratified the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 24,046,471 155,319 70,206 0